Ruxolitinib Clinical Trials
71 recruitingDrug
Phase 245Phase 129Phase 35Phase 42Early Phase 11
Showing 1–20 of 71 trials
Recruiting
Phase 2
A Study of Ruxolitinib for Preventing Graft-Versus-Host Disease in People With a Hematologic Malignancy Who Will Receive a Stem Cell Transplant
Hematologic Malignancies
Memorial Sloan Kettering Cancer Center40 enrolled7 locationsNCT07359859
Recruiting
Phase 1
A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma
Myelodysplastic SyndromeB-cell Non Hodgkin LymphomaRefractory Acute Myeloid Leukemia+16 more
Mayo Clinic99 enrolled2 locationsNCT03017820
Recruiting
Phase 2
A Randomized Study to Compare Post-transplant Cyclophosphamide, Sirolimus, Ruxolitinib and Post-transplant Cyclophosphamide, Sirolimus, Mycophenolate Mofetil to Prevent Graft Versus Host Disease
AML
M.D. Anderson Cancer Center80 enrolled1 locationNCT06973668
Recruiting
Phase 1Phase 2
JAK1/2 Inhibitor Ruxolitinib for Relapsed/Refractory Immune Bone Marrow Failure
Severe Aplastic AnemiaSingle Lineage Cytopenias, T-LGLHypoplastic MDS
National Heart, Lung, and Blood Institute (NHLBI)145 enrolled1 locationNCT05998408
Recruiting
Phase 3
A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)
Essential Thrombocythemia
Merck Sharp & Dohme LLC340 enrolled163 locationsNCT06079879
Recruiting
Phase 1Phase 2
Ruxolitinib-Enhanced Haplo HCT for Children and Young Adults With Sickle Cell Disease
Sickle Cell DiseaseGraft FailureHematopoetic Stem Cell Transplant+2 more
University of Colorado, Denver24 enrolled4 locationsNCT07252050
Recruiting
Phase 1
A Study to Evaluate Dermal Open-Flow Microperfusion and Plasma Pharmacokinetic Study of Multiple Doses of Oral Povorcitinib or Topical Ruxolitinib Cream in Healthy Adult Participants
Healthy Participants
Incyte Corporation24 enrolled1 locationNCT07588139
Recruiting
Phase 3
A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)
Primary myelofibrosis (PMF)Post-polycythemia Vera Myelofibrosis (PPV-MF)Post-essential Thrombocythemia Myelofibrosis (PET-MF)
Novartis Pharmaceuticals460 enrolled6 locationsNCT07357727
Recruiting
Phase 1
A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms
Neoplasms
Janssen Research & Development, LLC220 enrolled31 locationsNCT06150157
Recruiting
Phase 1Phase 2
Ruxolitinib and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer
Castration-Resistant Prostate CarcinomaStage IVB Prostate Cancer AJCC v8Metastatic Prostate Adenocarcinoma
University of Michigan Rogel Cancer Center20 enrolled3 locationsNCT06616155
Recruiting
Phase 1Phase 2
A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis
Myelofibrosis
Sumitomo Pharma America, Inc.240 enrolled84 locationsNCT04176198
Recruiting
Early Phase 1
Addition of Cord Blood Tissue-Derived Mesenchymal Stromal Cells to Ruxolitinib for the Treatment of Steroid-Refractory Acute Graft Versus Host Disease
Steroid refractory Graft Versus Host DiseaseHematopoietic and Lymphoid Cell Neoplasm
M.D. Anderson Cancer Center24 enrolled1 locationNCT04744116
Recruiting
Phase 3
MITHRIDATE: Ruxolitinib Versus Hydroxycarbamide or Interferon as First Line Therapy in High Risk Polycythemia Vera
Polycythemia Vera
University of Birmingham586 enrolled47 locationsNCT04116502
Recruiting
Phase 1
Study of Pelabresib add-on to Ruxolitinib in Japanese Adult Patients With Myelofibrosis
Primary myelofibrosis (PMF)Post-polycythemia Vera Myelofibrosis (Post-PV MF)Post-essential Thrombocythemia Myelofibrosis(Post-ET MF)
Novartis Pharmaceuticals6 enrolled6 locationsNCT07340138
Recruiting
Phase 2
Ruxolitinib in Previously Treated Idiopathic Multicentric Castleman Disease
Castleman's Disease (CD)Idiopathic Multicentric Castleman's Disease
University of Pennsylvania14 enrolled1 locationNCT07085039
Recruiting
Phase 2
Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma
Lymphoma
Memorial Sloan Kettering Cancer Center83 enrolled10 locationsNCT02974647
Recruiting
Phase 1
Ruxolitinib With and Without CTLA-4 Ig Abatacept for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation
Graft vs Host DiseaseGraft-Versus-Host Disease
Washington University School of Medicine41 enrolled1 locationNCT06008808
Recruiting
Phase 2
Ruxolitinib as First Line Treatment in Primary Haemophagocytic Lymphohistiocytosis (R-HLH)
Haemophagocytic Lymphohistiocytosis
Assistance Publique - Hôpitaux de Paris20 enrolled1 locationNCT05762640
Recruiting
Phase 1
Biomarker-Guided Ruxolitinib for the Prevention of Chronic Graft Versus Host Disease After Allogeneic Hematopoietic Cell Transplantation
Hematopoietic and Lymphatic System Neoplasm
City of Hope Medical Center42 enrolled1 locationNCT07025538
Recruiting
Phase 1Phase 2
Active Myeloid Target Compound Combinations in MDS/MPN Overlap Syndromes Overlap Syndromes (ABNL-MARRO)
MDS/MPN
Michael Savona94 enrolled4 locationsNCT04061421